| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | 2023年一季报 | |
|---|---|---|---|---|---|---|
| 营业收入(元) | ||||||
| 仿制药销售(元) | - | - | - | - | - | 13,408,040.31 |
| 研发服务收入(元) | - | - | - | - | - | 7,940,829.51 |
| 原料药销售(元) | - | - | - | - | - | 2,957,966.81 |
| 羟苯磺酸钙胶囊(元) | - | - | - | - | 31,289,731.59 | - |
| 羟苯磺酸钙原料药(元) | - | - | - | - | 5,586,018.22 | - |
| 眼用制剂(元) | - | - | - | - | 3,641,479.95 | - |
| 医药合同外包服务(元) | 17,115,823.99 | 19,385,803.61 | 12,181,094.68 | 41,462,096.83 | 17,802,173.01 | - |
| 吲达帕胺缓释片(元) | - | - | - | - | 5,435,776.15 | - |
| 化学药品制造(元) | 62,425,160.63 | 83,757,313.50 | 34,290,828.90 | 112,271,005.69 | - | - |
| 代加工收入(元) | - | 1,456,311.37 | - | - | - | - |
| 其他药品(元) | - | - | - | - | 2,085,265.13 | - |
| 营业成本(元) | ||||||
| 仿制药销售(元) | - | - | - | - | - | - |
| 研发服务收入(元) | - | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - | - |
| 羟苯磺酸钙胶囊(元) | - | - | - | - | 7,395,050.75 | - |
| 羟苯磺酸钙原料药(元) | - | - | - | - | 2,981,018.93 | - |
| 眼用制剂(元) | - | - | - | - | 2,213,082.36 | - |
| 医药合同外包服务(元) | 6,852,747.10 | 16,314,064.16 | 6,668,301.03 | 15,104,010.18 | 8,122,760.01 | - |
| 吲达帕胺缓释片(元) | - | - | - | - | 1,439,110.23 | - |
| 化学药品制造(元) | 23,490,588.16 | 28,450,406.84 | 12,186,877.03 | 38,652,393.66 | - | - |
| 代加工收入(元) | - | 1,079,758.63 | - | - | - | - |
| 其他药品(元) | - | - | - | - | 2,584,782.20 | - |
| 毛利(元) | ||||||
| 仿制药销售(元) | - | - | - | - | - | - |
| 研发服务收入(元) | - | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - | - |
| 羟苯磺酸钙胶囊(元) | - | - | - | - | 23,894,680.84 | - |
| 羟苯磺酸钙原料药(元) | - | - | - | - | 2,604,999.29 | - |
| 眼用制剂(元) | - | - | - | - | 1,428,397.59 | - |
| 医药合同外包服务(元) | 10,263,076.89 | 3,071,739.45 | 5,512,793.65 | 26,358,086.65 | 9,679,413.00 | - |
| 吲达帕胺缓释片(元) | - | - | - | - | 3,996,665.92 | - |
| 化学药品制造(元) | 38,934,572.47 | 55,306,906.66 | 22,103,951.87 | 73,618,612.03 | - | - |
| 代加工收入(元) | - | 376,552.74 | - | - | - | - |
| 其他药品(元) | - | - | - | - | -499,517.07 | - |
| 毛利率(%) | ||||||
| 仿制药销售(%) | - | - | - | - | - | - |
| 研发服务收入(%) | - | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - | - |
| 羟苯磺酸钙胶囊(%) | - | - | - | - | 76.37 | - |
| 羟苯磺酸钙原料药(%) | - | - | - | - | 46.63 | - |
| 眼用制剂(%) | - | - | - | - | 39.23 | - |
| 医药合同外包服务(%) | 59.96 | 15.85 | 45.26 | 63.57 | 54.37 | - |
| 吲达帕胺缓释片(%) | - | - | - | - | 73.53 | - |
| 化学药品制造(%) | 62.37 | 66.03 | 64.46 | 65.57 | - | - |
| 代加工收入(%) | - | 25.86 | - | - | - | - |
| 其他药品(%) | - | - | - | - | -23.95 | - |
| 收入构成(%) | ||||||
| 仿制药销售(%) | - | - | - | - | - | 55.16 |
| 研发服务收入(%) | - | - | - | - | - | 32.67 |
| 原料药销售(%) | - | - | - | - | - | 12.17 |
| 羟苯磺酸钙胶囊(%) | - | - | - | - | 47.52 | - |
| 羟苯磺酸钙原料药(%) | - | - | - | - | 8.48 | - |
| 眼用制剂(%) | - | - | - | - | 5.53 | - |
| 医药合同外包服务(%) | 21.52 | 18.53 | 26.21 | 26.97 | 27.04 | - |
| 吲达帕胺缓释片(%) | - | - | - | - | 8.26 | - |
| 化学药品制造(%) | 78.48 | 80.07 | 73.79 | 73.03 | - | - |
| 代加工收入(%) | - | 1.39 | - | - | - | - |
| 其他药品(%) | - | - | - | - | 3.17 | - |
| 毛利构成(%) | ||||||
| 仿制药销售(%) | - | - | - | - | - | - |
| 研发服务收入(%) | - | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - | - |
| 羟苯磺酸钙胶囊(%) | - | - | - | - | 58.13 | - |
| 羟苯磺酸钙原料药(%) | - | - | - | - | 6.34 | - |
| 眼用制剂(%) | - | - | - | - | 3.48 | - |
| 医药合同外包服务(%) | 20.86 | 5.23 | 19.96 | 26.36 | 23.55 | - |
| 吲达帕胺缓释片(%) | - | - | - | - | 9.72 | - |
| 化学药品制造(%) | 79.14 | 94.13 | 80.04 | 73.64 | - | - |
| 代加工收入(%) | - | 0.64 | - | - | - | - |
| 其他药品(%) | - | - | - | - | -1.22 | - |